CD4+ was associated with a lower risk of death for cancer of the oropharynx (pooled HR = 0.52; 95% CI: 0.31–0.89), but not of the oral cavity (pooled HR = 0.98; 95% CI: 0.96–1.00) and hypopharynx (pooled HR = 0.77; 95% CI: 0.49–1.20). This evidence concerns the gene CD4 and cancer.